

Capmatinib-associated interstitial lung disease in a patient with lung adenocarcinoma harboring a skipping mutation of mesenchymal-epithelial transition exon 14: A case report

BING-JIE LEE¹ and CHENG-YU CHANG^{2,3}

¹Department of Internal Medicine; ²Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 22000; ³Department of Nursing, Cardinal Tien Junior College of Healthcare and Management, New Taipei 23143, Taiwan, R.O.C.

Received June 1, 2023; Accepted July 31, 2023

DOI: 10.3892/ol.2023.14042

Abstract. Capmatinib is a medication used to treat patients with non-small cell lung cancer (NSCLC) who have a specific genetic mutation known as a mesenchymal-epithelial transition exon 14 skipping mutation. Previous clinical trials have reported that capmatinib treatment has a high objective response rate in patients with this genetic mutation. However, there have also been rare reports of patients developing interstitial lung disease (ILD) following capmatinib treatment, which can be life-threatening. The present case study reports the treatment of a patient who developed ILD after 6 weeks of capmatinib treatment for NSCLC, which was resolved following application of corticosteroids. The present case demonstrated that early recognition of the onset of ILD and discontinuation of capmatinib treatment, along with the prompt initiation of corticosteroid administration, can lead to complete resolution of ILD.

Introduction

Capmatinib is an anticancer medication used to treat certain types of cancer, particularly non-small cell lung cancer (NSCLC) involving a mesenchymal-epithelial transition (MET) exon 14 skipping mutation (1). This mutation leads to overexpression of the MET receptor tyrosine kinase, which is a protein that is involved in a number of important cellular processes, including cell growth,

survival and migration, and also promotes the formation of epithelial cells from mesenchymal cells (2). Capmatinib targets NSCLC tumors by inhibiting overactivity of c-Met and blocking tumor growth, and the results of a Phase Ib/II clinical trial previously reported that capmatinib has a high objective response rate in patients with MET exon 14 skipping NSCLC (3). Although capmatinib has demonstrated efficacy in treating NSCLC, side effects of this treatment have been reported. Common side effects include peripheral edema, nausea and a decreased appetite (3). A rare and potentially life-threatening side effect associated with capmatinib treatment is the development of interstitial lung disease (ILD). ILD is a broad term that describes a group of lung disorders that cause inflammation and scarring of the lung tissue, leading to breathing difficulties, coughing and fever (4). ILD can be caused by a variety of factors, such as exposure to environmental toxins and certain medications, including capmatinib (5). However, the incidence of capmatinib-induced ILD is low, with the few case reports that have been published all showing successful treatment with corticosteroids (6-8). However, given the potentially serious nature of this side effect, healthcare providers should be aware of this risk and closely monitor patients receiving capmatinib for signs or symptoms of ILD. Early recognition of the signs or symptoms of ILD, discontinuation of capmatinib treatment and the prompt initiation of corticosteroids have been reported to lead to complete resolution of ILD (4).

Case report

A 50-year-old man with a history of hypertension and a past history of smoking presented to Far Eastern Memorial Hospital (New Taipei City, Taiwan) in March 2018 with the chief complaint of coughing that had persisted for 2 months. The patient smoked one pack of cigarettes/day for 2 years, before quitting smoking 25 years prior to hospital admission. A chest X-ray showed a right upper lobe mass of 3.3 cm and subsequent chest computed tomography (CT) showed multiple nodules, with the largest measuring 3.3 cm in the right upper lobe. The patient was subsequently

Correspondence to: Dr Cheng-Yu Chang, Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, 21, Section 2, Nan-Ya South Road, Banqiao, New Taipei City 22000, Taiwan, R.O.C.
E-mail: koala2716@hotmail.com

Key words: capmatinib, interstitial lung disease, mesenchymal-epithelial transition inhibitor, mesenchymal-epithelial transition exon 14 skipping

diagnosed with adenocarcinoma after a CT-guided biopsy in April 2018. The patient underwent a right upper lobe video-assisted thoracoscopic surgery lobectomy with radical lymph node dissection and was diagnosed with pathological stage IB T2aN0M0 (9) adenocarcinoma according to the 8th edition American Joint Committee on Cancer Tumor-Node-Metastasis system, with no mutation of EGFR, anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1). Due to the healthcare insurance system in Taiwan, following surgical resection of early stage lung cancer, genetic testing was limited to individual testing of commonly observed genes. Adjuvant chemotherapy with Ufur (tegafur, 100 mg; uracil, 224 mg) twice daily was administered to the patient between September 2018 and August 2019, without any evidence of recurrence of the disease. Further CT scans performed in May and November 2020 demonstrated stable disease with no recurrence observed.

However, in May 2021, the patient developed progressive disease with right-sided pleural effusion and small nodules in the left lower lobe. Analysis of the malignant pleural effusion revealed persistent adenocarcinoma via cytology and cell block: Samples were fixed in 10% formalin at 25°C for 24 h and sliced into 4- to 5- μ m thick sections. Hematoxylin and eosin staining was applied at 25°C, with hematoxylin used for 1-2 min and eosin for 30 sec. A light field microscope was used to visualize the results. There were no mutations of EGFR, ALK or ROS-1, although the patient was now programmed cell death-ligand 1 (PD-L1)-positive, with a tumor proportion score of $\geq 50\%$. The patient received 500 mg pemetrexed and 75 mg *cis*-platinum (per m² body surface area, every 3 weeks, in an infusion for 6 cycles) between June 2021 and October 2021, followed by nivolumab between November 2021 and September 2022. The patient then presented with left-sided weakness, slurred speech and an imbalanced gait for 1 week in October 2022. A brain CT showed right temporal, left frontal and left cerebellar metastasis, with a midline shift towards the left side of ~ 13 mm. The patient underwent a right temporal craniotomy for right temporal tumor excision in October 2022, followed by stereotactic body radiation therapy, with a total of 2,500 cGy administered in five fractions. The pathology of the brain tumor demonstrated metastatic carcinoma and the results of ACTDrug[®]+ next-generation sequencing-based assay (performed by ACT Genomics, Co. Ltd.) demonstrated the presence of the MET exon 14 skipping mutation. The patient was then prescribed capmatinib (200 mg/three times daily) in November 2022.

The patient was again admitted to hospital in January 2023 due to progressive dyspnea, and treatment with capmatinib was maintained up to January 2023. A chest X-ray showed bilateral infiltrations. Chest CT scan images showed extensive ground-glass opacity in both lungs and subpleural consolidation, which led to a suspected diagnosis of drug-induced ILD and pneumonia (Fig. 1). The patient was tested for influenza A and B, coronavirus disease 2019, and *Legionella* and *Mycoplasma* antibodies, which are potential causes of ILD and were common tests conducted in Taiwan in 2021; however, these tests were negative. Systemic steroids consisting of 120 mg methylprednisolone

per day and antibiotics consisting of 750 mg levofloxacin per day were then prescribed and the patient's oxygenation status improved. The follow-up chest X-ray also showed improvement of the bilateral infiltrations. Antibiotics were discontinued and systemic steroids were gradually titrated until the patient was only receiving oral prednisolone. The follow-up chest CT images demonstrated marked regressive changes in the bilateral ground-glass opacity (Fig. 2). The patient was discharged after 14 days of treatment. Treatment with oral tepotinib, another type of MET inhibitor, was provided once daily [administered as two 225 mg tablets (450 mg)] for 21 days at 1 month post-discontinuation of capmatinib treatment. The patient undergoes monthly follow-up chest X-rays, with chest CT scans every 3 months. The last follow-up was in June 2023, and currently, there are no signs of ILD.

Discussion

The development of ILD is a rare but serious side effect associated with the use of capmatinib for NSCLC. Although the incidence of ILD caused by capmatinib treatment is low (three reported cases), it is important for healthcare providers to be aware of the potential risks and to monitor patients closely for signs and symptoms of ILD. There were three case reports that emphasized the emergence of ILD due to capmatinib therapy. Among these, two cases saw resolution after undergoing corticosteroid treatment, while another two cases exhibited a successful shift to tepotinib as an alternative targeted therapy. These findings closely parallel the conclusions drawn in our article (6-8). Both the prompt recognition of signs and symptoms of ILD and the management of capmatinib-induced ILD is crucial to avoid potential complications of this condition and to ensure the best possible outcomes for patients (4,6-8). The discontinuation of capmatinib treatment and prompt initiation of corticosteroid treatment can lead to complete resolution of ILD in certain cases, as demonstrated in the present case report.

The primary emphasis in ILD metabolomics research has centered around the examination of lung tissue, bronchoalveolar lavage fluid and exhaled breath condensate samples derived from individuals suffering from idiopathic pulmonary fibrosis, the prevailing subtype among ILD cases (10). By conducting a thorough analysis of protein precipitation of serum samples, it has been reported that lysophosphatidylcholine (LysoPC), a substance that acts as a precursor for lysophosphatic acid, serves a pivotal role in distinguishing between patients and healthy controls (11). This highlights the significance of LysoPC as a potential biomarker for identifying individuals affected by the condition, providing valuable insights into the underlying mechanisms of the disease and offering a promising avenue for further diagnostic and therapeutic developments in the field of medical research (11).

Given the potential risk of ILD with capmatinib treatment, it is important for healthcare providers to educate patients on the signs and symptoms of this condition and to encourage patients to promptly report any concerns. Further research is needed to better understand the risk factors, pathophysiology




Figure 1. Chest computed tomography images. Extensive ground-glass opacity in both lungs and subpleural consolidation were observed (arrows), which was suspected to be drug-induced interstitial lung disease and pneumonia.




Figure 2. Chest computed tomography images. Marked regressive changes were observed in the bilateral ground-glass opacity previously exhibited by the patient (arrows).

and optimal management of this rare but serious side effect of capmatinib treatment.

In conclusion, the present case report demonstrates the potential for capmatinib to cause ILD, a rare but serious side effect resulting from the administration of capmatinib treatment. Early recognition of ILD and discontinuation of the capmatinib treatment, in addition to the prompt administration of corticosteroids, can lead to complete resolution of ILD. Healthcare providers should closely monitor patients taking capmatinib for any signs or symptoms of ILD.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors' contributions

CYC designed the study, revised the manuscript for intellectual content and gave final approval for publication. BJL obtained medical images, analyzed patient data and drafted the manuscript. CYC and BJL confirm the authenticity of all

the raw data. Both authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

The patient provided written informed consent for this case study to be published.

Competing interests

The authors declare that they have no competing interests.

References

1. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJ, Tan DSW, Hida T, de Jonge M, Orlov SV, *et al*: Capmatinib (INC280) in patients (pts) with METex14-mutated advanced NSCLC: An update from phase 2 GEOMETRY mono-1 study. *Pneumologie* 74 (S 01): S134, 2020.
2. Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, *et al*: Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. *Mol Cancer* 17: 45, 2018.
3. Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, *et al*: Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. *J Clin Oncol* 36: 3101-3109, 2018.
4. Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, *et al*: Consensus statement for the diagnosis and treatment of drug-induced lung injuries. *Respir Investig* 51: 260-277, 2013.
5. Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U and Poletti V: Interstitial lung disease. *Eur Respir Rev* 23: 40-54, 2014.
6. Kanemura H, Takeda M, Shimizu S and Nakagawa K: Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14. *Thorac Cancer* 12: 549-552, 2021.
7. Hashiguchi MH, Sato T, Yamamoto H, Watanabe R, Kagyo J, Domoto H and Shiomi T: Successful tepotinib challenge after capmatinib-induced interstitial lung disease in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation: Case report. *JTO Clin Res Rep* 3: 100271, 2021.
8. Tseng LW, Chang JWC and Wu CE: Safety of tepotinib challenge after capmatinib-induced pneumonitis in a patient with non-small cell lung cancer harboring MET exon 14 skipping mutation: A case report. *Int J Mol Sci* 23: 11809, 2022.
9. Amin MB, Greene FL, Edge SB, Compton CC, Gershengrad JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more 'personalized' approach to cancer staging. *CA Cancer J Clin* 67: 93-99, 2017.
10. Kang YP, Lee SB, Lee JM, Kim HM, Hong JY, Lee WJ, Choi CW, Shin HK, Kim DJ, Koh ES, *et al*: Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. *J Proteome Res* 15: 1717-1724, 2016.
11. Rindlisbacher B, Schmid C, Geiser T, Bovet C and Funke-Chambour M: Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis—a potential biomarker role for LysoPC. *Respir Res* 19: 7, 2018.



Copyright © 2023 Lee and Chang. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.